Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

Hedwig Blommestein; N Armstrong; S Ryder; S Deshpande; G Worthy; C Noake; R Riemsma; J Kleijnen; Hans Severens; Maiwenn Al

doi:10.1007/s40273-015-0318-3

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

Hedwig Blommestein, N Armstrong, S Ryder, S Deshpande, G Worthy, C Noake, R Riemsma, J Kleijnen, Hans Severens, Maiwenn Al

Health Technology Assessment (HTA)

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

7 Downloads (Pure)

Original language	English
Pages (from-to)	23-31
Number of pages	9
Journal	Pharmacoeconomics (Online)
Volume	34
Issue number	1
DOIs	https://doi.org/10.1007/s40273-015-0318-3
Publication status	Published - 2016

Access to Document

10.1007/s40273-015-0318-3

REPUB_91665_OA.pdfFinal published version, 435 KB

http://hdl.handle.net/1765/91665

Cite this

Blommestein, H., Armstrong, N., Ryder, S., Deshpande, S., Worthy, G., Noake, C., Riemsma, R., Kleijnen, J., Severens, H., & Al, M. (2016). Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. Pharmacoeconomics (Online), 34(1), 23-31. https://doi.org/10.1007/s40273-015-0318-3

@article{65254815d3344566bbb00279d041359d,

title = "Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene",

author = "Hedwig Blommestein and N Armstrong and S Ryder and S Deshpande and G Worthy and C Noake and R Riemsma and J Kleijnen and Hans Severens and Maiwenn Al",

year = "2016",

doi = "10.1007/s40273-015-0318-3",

language = "English",

volume = "34",

pages = "23--31",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis",

number = "1",

}

Blommestein, H, Armstrong, N, Ryder, S, Deshpande, S, Worthy, G, Noake, C, Riemsma, R, Kleijnen, J, Severens, H & Al, M 2016, 'Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene', Pharmacoeconomics (Online), vol. 34, no. 1, pp. 23-31. https://doi.org/10.1007/s40273-015-0318-3

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. / Blommestein, Hedwig; Armstrong, N; Ryder, S et al.
In: Pharmacoeconomics (Online), Vol. 34, No. 1, 2016, p. 23-31.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

AU - Blommestein, Hedwig

AU - Armstrong, N

AU - Ryder, S

AU - Deshpande, S

AU - Worthy, G

AU - Noake, C

AU - Riemsma, R

AU - Kleijnen, J

AU - Severens, Hans

AU - Al, Maiwenn

PY - 2016

Y1 - 2016

U2 - 10.1007/s40273-015-0318-3

DO - 10.1007/s40273-015-0318-3

M3 - Article

SN - 1170-7690

VL - 34

SP - 23

EP - 31

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 1

ER -